The primary goal of this project is to test our core hypothesis that brain iron accumulation in Huntington's disease (HD) promotes disease onset and progression. HD is an ultimately fatal neurodegenerative disease that afflicts about 30000 people in the USA alone and has no effective treatments. CAG-repeat expansion within the huntingtin gene results in expression of a polyglutamine-expanded mutant huntingtin protein leading to a number of downstream effects including energetic dysregulation, aberrant glutamate signaling, iron elevation, oxidative and nitrosative stress, and eventually neuronal degeneration and loss. There is growing evidence that dysregulation of iron homeostasis contributes to the pathogenesis of HD as well as ALS, Parkinson's and Alzheimer's diseases. Surprisingly however, little is known about how this occurs in HD and to what degree iron dysregulation contributes to the overall disease process. We have shown for the first time that iron accumulates in mouse HD striatal and cortical neurons, regions where there is significant degeneration. Amyloid precursor protein (APP) has a key role in neuronal iron export. We show significantly decreased levels of APP as well as its iron export ferroxidase activity. We have also demonstrated elevated iron in an inducible mutant huntingtin expressing cell line and shown that nNOS inhibition reverses this. These interesting and important findings point to a link between nitric oxide, APP and iron in HD and form the basis for the proposed studies.
Aim 1 will test the hypothesis that nitrosative stress mediates decreased APP protein levels resulting in elevated iron which potentiates neurodegeneration.
In Aim 1 A we will determine the effect of genetic modulation of APP on outcomes in HD models.
In Aim 1 B we study the effects of nNOS inhibition on HD outcomes including APP and iron. We will use transgenic and full-length mutant huntingtin mouse models as well as HD cell lines and primary neuron cultures.
Aim 2 will test the hypothesis that nutritionally relevant elevated iron intake potentiates brain iron accumulation and neurodegeneration in HD mice. The studies will provide important insights into mechanisms of iron dysregulation in HD. Findings will determine the extent to which dysregulated iron in HD brain potentiates disease;they may validate APP as a novel therapeutic target as well as provide insight into modulatory effects of dietary iron in HD.
Huntington's disease (HD) is a progressive and fatal neurodegenerative disease that is caused by a mutation resulting in a polyglutamine expansion within huntingtin protein. There is growing evidence that mutant huntingtin protein disrupts iron homeostasis in HD and that this contributes to disease onset and progression. The goal of this research is to elucidate mechanisms of iron dyshomeostasis in HD and to identify therapeutic approaches that may have protective effects in human HD patients.
|Berggren, Kiersten; Agrawal, Sonal; Fox, Julia A et al. (2017) Amyloid Precursor Protein Haploinsufficiency Preferentially Mediates Brain Iron Accumulation in Mice Transgenic for The Huntington's Disease Mutation. J Huntingtons Dis 6:115-125|
|Agrawal, Sonal; Berggren, Kiersten L; Marks, Eileen et al. (2017) Impact of high iron intake on cognition and neurodegeneration in humans and in animal models: a systematic review. Nutr Rev 75:456-470|
|Berggren, Kiersten L; Lu, Zhen; Fox, Julia A et al. (2016) Neonatal Iron Supplementation Induces Striatal Atrophy in Female YAC128 Huntington's Disease Mice. J Huntingtons Dis 5:53-63|
|Berggren, Kiersten L; Chen, Jianfang; Fox, Julia et al. (2015) Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease. Redox Biol 4:363-74|
|Dodds, Lindsay; Chen, Jianfang; Berggren, Kiersten et al. (2014) Characterization of Striatal Neuronal Loss and Atrophy in the R6/2 Mouse Model of Huntington's Disease. PLoS Curr 6:|
|Chen, Jianfang; Marks, Eileen; Lai, Barry et al. (2013) Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One 8:e77023|